AusperBio, a biotech startup, has secured $73 million in Series B funding for advancing its innovative AHB-137 treatment as a potential hepatitis B cure, targeting chronic hepatitis B with new therapies that could transform lives and expand the possibilities of biotech in curing various diseases.
AusperBio, operating in the USA and China, seeks groundbreaking treatment for chronic hepatitis B (CHB). The company’s lead therapy, AHB-137, aims to bring patients closer to a long-awaited functional cure, offering hope to millions worldwide.
This funding round, led by HanKang Capital, attracted investments from Sherpa Capital, CDH Investments, and other major players, including returning backers Qiming Venture Partners, InnoPinnacle Fund, and YuanBio Venture Capital. The new funding will boost clinical trials for AHB-137 and support the company’s plans for large-scale manufacturing and expanded research.
Tackling Hepatitis B with Cutting-Edge Science
AusperBio’s AHB-137 is a next-generation treatment designed to target the root causes of chronic hepatitis B. Unlike traditional treatments that manage symptoms, this therapy aims to stop the disease altogether. Recent studies have shown promising results, and AHB-137 is now being tested in advanced trials in China.
The therapy has gained attention at prestigious medical conferences worldwide, including the 2024 AASLD meeting, where experts praised its potential. Co-founder and CEO Dr. Guofeng Cheng said, “This funding brings us closer to our goal of curing hepatitis B and improving the lives of millions affected by this disease.”
AusperBio isn’t stopping with hepatitis B. The company uses its innovative technology to develop treatments for conditions like genetic and immune system diseases. Dr. Chris Yang, co-founder and CSO, added, “Our work on AHB-137 showcases the power of our platform to create therapies that truly make a difference.”
This milestone marks a significant step toward a hepatitis B cure while opening doors for new treatments that could transform lives across the globe.
Follow USTechTimes on Facebook, Twitter and Linkedin for in-depth news of market trends, funding updates, and regulatory changes affecting startups in USA.
We Recommend:
- Mission Bio Raises $70M in Series C Funding Led by Novo Holdings
- Guardant Health invests $26 million in health-tech startup Lunit
- Renibus Therapeutics secures $47M funding to advance promising drug for postoperative complications following cardiothoracic surgery
- HyAxiom ignites innovation with $150M funding round for fuel cell solutions
- Augmedics raises $82.5m in Series D funding for augmented reality surgical navigation platform
